Phage-Bacteria Interplay: Phage Biology and Phage Therapy

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Virology".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 583

Special Issue Editors


E-Mail Website
Guest Editor
Department of Surgery, Division of Orthopaedics, The Ottawa Hospital, Ottawa, ON, Canada
Interests: phage; periprosthetic infections
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Ottawa Hospital Research Institute, Ottawa, ON, Canada
Interests: phage; biofilm

Special Issue Information

Dear Colleagues,

Bacteriophages (phages) are naturally occurring viruses that specifically infect and replicate within bacterial cells. Phages play a crucial role in shaping microbial communities and influencing bacterial evolution. Over the past few years, there has been a surge in exploring the therapeutic potential of phages against antibiotic-resistant bacteria.

This Special Issue entitled “Phage–Bacteria Interplay: Phage Biology and Phage Therapy” aims to present recent research related to phages with special focus on, but not limited to, the following areas: phage genomics, phage diversity, phage therapy, phage–host interactions, phage-mediated horizontal gene transfer, diverse mechanisms of phage infection, microbiome, replication and interaction with bacterial hosts. This Special Issue is devoted to publishing papers on studies of the biology, therapy and application of phages. Reviews, original research and communications will be welcome.

Dr. Hesham Abdelbary
Dr. Mariam Taha
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microbiome
  • phage therapy
  • phage resistance
  • phage biology
  • phage engineering

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3411 KiB  
Article
Salmonella Phage vB_SpuM_X5: A Novel Approach to Reducing Salmonella Biofilms with Implications for Food Safety
by Xinxin Jin, Xiuxiu Sun, Qin Lu, Zui Wang, Zhenggang Zhang, Xiaochun Ling, Yunpeng Xu, Ruiqin Liang, Junjie Yang, Li Li, Tengfei Zhang, Qingping Luo and Guofu Cheng
Microorganisms 2024, 12(12), 2400; https://doi.org/10.3390/microorganisms12122400 - 22 Nov 2024
Abstract
Salmonella, a prevalent foodborne pathogen, poses a significant social and economic strain on both food safety and public health. The application of phages in the control of foodborne pathogens represents an emerging research area. In this study, Salmonella pullorum phage vB_SpuM_X5 (phage [...] Read more.
Salmonella, a prevalent foodborne pathogen, poses a significant social and economic strain on both food safety and public health. The application of phages in the control of foodborne pathogens represents an emerging research area. In this study, Salmonella pullorum phage vB_SpuM_X5 (phage X5) was isolated from chicken farm sewage samples. The results revealed that phage X5 is a novel Myoviridae phage. Phage X5 has adequate temperature tolerance (28 °C–60 °C), pH stability (4–12), and a broad host range of Salmonella bacteria (87.50% of tested strains). The addition of phage X5 (MOI of 100 and 1000) to milk inoculated with Salmonella reduced the number of Salmonella by 0.72 to 0.93 log10 CFU/mL and 0.66 to 1.06 log10 CFU/mL at 4 °C and 25 °C, respectively. The addition of phage X5 (MOI of 100 and 1000) to chicken breast inoculated with Salmonella reduced bacterial numbers by 1.13 to 2.42 log10 CFU/mL and 0.81 to 1.25 log10 CFU/mL at 4 °C and 25 °C, respectively. Phage X5 has bactericidal activity against Salmonella and can be used as a potential biological bacteriostatic agent to remove mature biofilms of Salmonella or for the prevention and control of Salmonella. Full article
(This article belongs to the Special Issue Phage-Bacteria Interplay: Phage Biology and Phage Therapy)
Show Figures

Figure 1

Back to TopTop